These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 22044445

  • 1. Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project.
    Fischer K, Lewandowski D, Marijke van den Berg H, Janssen MP.
    Haemophilia; 2012 May; 18(3):e241-6. PubMed ID: 22044445
    [Abstract] [Full Text] [Related]

  • 2. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.
    Fischer K, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Iorio A, Gilman E, Makris M, EUHASS participants.
    Thromb Haemost; 2015 May; 113(5):968-75. PubMed ID: 25567324
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Inhibitor development in non-severe haemophilia across Europe.
    Fischer K, Iorio A, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Gilman EA, Hollingsworth R, Makris M, EUHASS Participants.
    Thromb Haemost; 2015 Oct; 114(4):670-5. PubMed ID: 26293381
    [Abstract] [Full Text] [Related]

  • 6. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.
    Chalmers EA, Brown SA, Keeling D, Liesner R, Richards M, Stirling D, Thomas A, Vidler V, Williams MD, Young D, Paediatric Working Party of UKHCDO.
    Haemophilia; 2007 Mar; 13(2):149-55. PubMed ID: 17286767
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Epidemiology of inhibitors in haemophilia A.
    Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer I, Güngör T, Kornhuber B.
    Vox Sang; 1996 Mar; 70 Suppl 1():2-8. PubMed ID: 8869461
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
    Bacon CL, Singleton E, Brady B, White B, Nolan B, Gilmore RM, Ryan C, Keohane C, Jenkins PV, O'Donnell JS.
    Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
    Shirahata A, Fukutake K, Higasa S, Mimaya J, Oka T, Shima M, Takamatsu J, Taki M, Taneichi M, Yoshioka A, STUDY GROUP ON FACTORS INVOLVED IN FORMATION OF INHIBITORS TO FACTOR VIII AND IX PREPARATIONS.
    Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
    [Abstract] [Full Text] [Related]

  • 15. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.
    Peerlinck K, Arnout J, Di Giambattista M, Gilles JG, Laub R, Jacquemin M, Saint-Remy JM, Vermylen J.
    Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Low prevalence of inhibitor antibodies in the Canadian haemophilia population.
    Webert KE, Rivard GE, Teitel J, Carcao M, Lillicrap D, St-Louis J, Walker IR.
    Haemophilia; 2012 May; 18(3):e254-9. PubMed ID: 22077390
    [Abstract] [Full Text] [Related]

  • 18. Characteristics of inhibitors in mild/moderate haemophilia A.
    Peerlinck K, Jacquemin M.
    Haemophilia; 2006 Dec; 12 Suppl 6():43-7. PubMed ID: 17123393
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.